C ancer-induced T cell dysfunction facilitates tumor immune escape 1,2 and can be particularly severe in patients with GBM 3-6 . Despite near universal confinement to the intracranial compartment 7 , GBM frequently depletes systemic T cells of both number and function. Regarding the former, T cell lymphopenia is prominent but has remained incompletely explained for four decades 8 .
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NATure MeDICINe (1) GBM diagnosis, (2) complete blood counts at presentation, and (3) computed tomography scan of the chest/abdomen/pelvis. Lymphocyte counts and splenic volumes were assessed. GBM subject data were compared to all trauma patients evaluated in the emergency department over the same ten-year period fitting the same age range and with a complete blood count and normal abdominal computed tomography imaging, as determined by a radiologist. Exclusion criteria for both cohorts included history of autoimmune disorder, immune deficiency, hematologic cancer, splenic injury, active infection, or chemotherapy. Ultimately, 300 subjects with GBM and 46 controls satisfied the above inclusion criteria ( Supplementary Table 1 ); numbers were not determined a priori. Spleen volumes were determinable in 278 subjects and 43 controls; dexamethasone exposure/dosing information was available for 284 subjects.
Generalized lymphopenia was present in treatment-naïve GBM subjects, with treatment-naïve defined as no prior biopsy, resection, chemotherapy, or radiation. As some subjects had been diagnosed at outside hospitals before presentation, previous dexamethasone exposure varied. Subjects were divided into those entirely dexamethasone-naïve versus those receiving at least a single dose of dexamethasone. Lymphopenia was present in 24.7% of all GBM subjects (18.2% of dexamethasone-naïve; 37.1% of dexamethasone-experienced) compared to 10.9% of controls, with lymphopenia defined as lymphocyte count < 1,000 cells μ l −1 ) ( Supplementary Fig. 1a) .
To examine T cell counts specifically, we prospectively studied a new cohort of treatment-naïve subjects with GBM (n = 15), as well as controls meeting similar demographics (n = 13) (Supplementary Table 2 ). Subjects were dexamethasone-naïve and demonstrated a prevalent, severe reduction in T cell counts, with a mean CD4 count of 411 cells μ l −1 (control mean 962 cells μ l −1 ). CD8 counts were also significantly lower in patients than controls ( Fig. 1a) . Notably, ~15% of treatment-naïve GBM subjects presented with CD4 counts less than 200 cells μ l −1 , the threshold demarcating AIDS in human immunodeficiency virusinfected individuals. T cell loss trended towards being more severe among naïve T cells (CD27 + CD45RA + ) than among memory (CD45RO + ), with patients exhibiting decreased ratios of naïve to memory T cells compared to controls ( Supplementary Fig. 1b,c) .
We hypothesized that splenic sequestration might explain the T cell lymphopenia, with resultant splenomegaly. To the contrary, returning to the retrospective dataset, we observed that splenic volume was markedly contracted in GBM subjects (32% mean size reduction), with an overall mean of 217.1 ml compared to 317.3 ml in controls ( Fig. 1b ). Splenic volume in subjects was not influenced by dexamethasone exposure (214.4 ml in dexamethasone-naïve, 219.3 ml in dexamethasone-experienced; Supplementary Fig. 1d ).
Recapitulated T cell lymphopenia and lymphoid organ contraction in murine glioma. To assess for similar changes in murine glioma models, SMA-560 or CT2A murine glioma cells were implanted stereotactically into the brains (intracranial) of syngeneic VM/Dk or C57BL/6 mice, respectively. Blood, spleen, cervical lymph nodes (CLNs), and thymus were analyzed once tumors had become sizeable (day [18] [19] [20] . Mice were exclusively treatmentnaïve. Both tumor models demonstrated significant T cell lymphopenia in the CD4 and CD8 compartments ( Fig. 2a,b ). As with patients, naïve (CD62L hi CD44 lo ) T cell numbers were more prominently diminished. Memory (CD44 hi ) T cell counts were not significantly reduced ( Supplementary Fig. 2a ). The splenic contraction observed in subjects with GBM was recapitulated in mice ( Fig. 2c) , and volume contractions further typified CLN and thymus (thymus depicted in Supplementary Fig. 2c ).
Accompanying the volume reductions in lymphoid organs were significant decreases to organ T cell counts (spleen counts depicted in Supplementary Fig. 2b ). Histologic examination and immunohistochemical staining of spleen, thymus, and CLN revealed marked lymphodepletion, primarily in T cell-dependent areas. Lymphoid necrosis was also present ( Fig. 2d and Supplementary Fig. 2d ). Severe T cell disappearance thus appeared systemic, characterizing both blood and lymphoid organs.
Naïve T cells accumulate in the bone marrow of mice and subjects with GBM.
Diminished naïve T cell counts suggested deficient production, leading us to investigate the bone marrow of gliomabearing mice for T cell-progenitor frequencies. This analysis instead revealed that naïve T cell disappearance from blood and lymphoid organs was met conversely with three-to fivefold expansions of mature, single-positive T cell numbers within the bone marrow of mice bearing either SMA-560 or CT2A intracranially ( Fig. 3a and sample flow cytometry in Supplementary Fig. 3a ). Immune cell accumulation in the bone marrow was T cell specific, with no increases observed for natural killer cells, B cells, or granulocytes/ monocytes ( Supplementary Fig. 3b ). Both CD4 + and CD8 + T cells accumulated (Fig. 3b ), albeit disproportionately for those with a naïve phenotype (CD44 lo CD62L hi ) ( Fig. 3c) . A time course for T cell accumulation is provided in Supplementary Fig. 3c .
This finding being unexpected, we investigated whether it was mirrored in subjects with GBM. Blood and bone marrow aspirates were collected from 15 treatment-naïve GBM subjects and 15 healthy controls undergoing spinal fusion (from whom bone marrow aspirates are often collected intraoperatively for employment in fusion constructs). All bone marrow was harvested from patients and controls following the induction of general anesthesia for their respective surgeries (resection or fusion). Aspirates were collected from the iliac crest before incision or administration of any indicated intraoperative steroids. Samples were analyzed by flow cytometry.
In subjects with GBM, we uncovered a significant re-allocation of T cells to bone marrow, compared to blood. While bone marrow T cell counts varied widely among all individuals, controls typically had matching T cell counts across bone marrow and blood (median marrow to blood ratio for CD4 + T cells, 1.06:1; for CD8 + T cells, 1.42:1). This homeostasis was disrupted in GBM subjects, who nearly universally had higher T cell counts in their bone marrow, 
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with marrow to blood ratios ranging as high as 20:1 (Fig. 3d ). In GBM subjects, there was a consistent increase in both CD4 and CD8 counts as one moved from blood to bone marrow (P < 0.0001 and P = 0.0007, respectively, Wilcoxon matched-pairs signed rank test; CD4 + T cells depicted in Fig. 3e ). Indeed, 14 of 15 GBM subjects had higher T cell counts in bone marrow than in blood, while for controls this was true in only 8 of 15 (P = 0.01, chi-squared analysis). As with mice, naïve (CD27 + CD45RA + ) T cells were over-represented in the bone marrow (CD4 + T cells depicted in Fig. 3f , sample flow cytometry depicted in Supplementary Fig. 3d ). Exploring CD4 subsets, we found no difference in the counts of bone marrow regulatory T (Treg) cells across patients and controls ( Fig. 3g ). Although most T cells detected in marrow were naïve, we analyzed differentiated CD4 + helper T cell (Th1, 2, or 17) subsets, finding no substantial differences in the relative representation of each across the bone marrow of patients and controls ( Fig. 3h ).
T cell accumulation in bone marrow reflects intracranial tumor location rather than tumor histologic type.
We examined whether accumulation of T cells in bone marrow characterized cancer more generally or, rather, was specific to either glioma or the intracranial tumor environment. To test this, E0771 breast carcinoma, B16F10 melanoma, Lewis lung carcinoma (LLC), or CT2A gliomas were each implanted either intracranially or subcutaneously into syngeneic C57BL/6 mice and bone marrow T cell frequency assessed. Notably, each intracranial tumor provoked significant accumulation of T cells in bone marrow, regardless of the primary tumor type. Conversely, none of the subcutaneously-situated tumors, including glioma, evoked the same phenomenon ( Fig. 4a ). Control intracranial injections with saline and methycellulose produced no increase in bone marrow T cell numbers ( Supplementary Fig. 4a ). CD4 + and CD8 + T cells accumulated in the bone marrow in approximately equal proportions across all tumor types ( Fig. 4b ), but, for all models, accumulating T cells were disproportionatley naïve (CD44 lo CD62L hi ) (Fig. 4c ).
The accumulation of largely naïve T cells in the bone marrow suggested homing or sequestration, rather than in situ antigendriven expansion. We therefore investigated whether adoptively transferred naïve T cells would likewise preferentially collect in the bone marrow of glioma-bearing mice. Naïve C57BL/6 spleens were harvested as a source of donor leukocytes. Cells (1 × 10 7 ) were 5(6)-carboxyfluorescein N-hydroxysuccinimidyl ester (CFSE)labeled and injected via tail vein into naïve control mice or mice bearing CT2A glioma intracranially or subcutaneously. At 24 h, analysis revealed increased numbers of labeled T cells in the bone marrow uniquely in hosts bearing CT2A intracranially, and not in Articles NATure MeDICINe hosts bearing CT2A subcutaneously (Fig. 4d ). This experiment was repeated with intracranial CT2A recipient mice, assessing at time points 2 h and 24 h post-transfer. Although present again in marrow at 24 h, labeled T cells failed to accumulate in the bone marrow at the 2-hour time point, suggesting T cell trapping or sequestration rather than direct bone marrow homing ( Fig. 4e) . As a crossover, T cells that had accumulated within the bone marrow of glioma-bearing mice were collected, enriched, labeled with CFSE, and injected into tail veins of naïve control mice. T cells that had accumulated in the bone marrow of glioma-bearing mice re-accumulated within the marrow of naïve mice with equivalent efficiency. Transferring the same cells into tumor-bearing hosts yielded no further increase in marrow accumulation (Fig. 4f) . These experiments suggested the acquisition of T cell phenotypic changes precipitating their sequestration rather than changes to the bone marrow itself (see schematic in Supplementary Fig. 4b ).
Loss of surface S1P1 on T cells directs their sequestration in bone marrow in the setting of intracranial tumors.
As the experiments in Fig. 4d -f suggested that T cells acquire alterations facilitating their sequestration in the glioma-bearing state, we hypothesized that the relevant alteration might be diminished levels of surface S1P1 (we had previously investigated the CXCR4-CXCL12 axis, failing to find a relationship) ( Supplementary Fig. 5a ). A role for the S1P-S1P1 axis mediating bone marrow T cell egress has been observed in alymphoplastic mice lacking thymus and secondary lymphoid organs (SLOs) 18 , a phenotype paralleling the lymphoid organ contraction we observed with GBM. We conjectured that a similar shift in control of T cell bone marrow egress to the S1P-S1P1 axis might occur with GBM, with disruption to that axis instead fostering T cell sequestration within the marrow.
Surface S1P1 levels were assessed on T cells in the bone marrow of control mice and mice bearing intracranial CT2A glioma. For the detection of otherwise fleeting S1P1 on the cell surface by flow cytometry, we employed a reliable technique in which all harvested tissues were immediately placed into a fixative solution to cross-link surface molecules, and in which no solutions contained FCS in order to avoid ligand-induced internalization 19 . Mice with intracranial CT2A demonstrated markedly reduced T cell S1P1 levels in bone marrow ( Fig. 5a,b ) and moderately reduced T cell S1P1 levels in contracted spleens and CLN ( Supplementary Fig. 5b ).
Loss of S1P1 might result from changes to gene expression or from alterations at the protein level (increased receptor internalization or decreased recycling). To assay for altered S1pr1 expression (the gene encoding S1P1), we performed qPCR with reverse transcription of T cells sorted from the spleens of control and gliomabearing mice. No differences in S1pr1 transcript numbers were detected ( Supplementary Fig. 5c ). Likewise, RNA flow cytometry of T cells revealed no differences in levels of the upstream S1pr1 modulators CD69, KLF2, or STAT3 ( Supplementary Fig. 5d ).
As S1P1 receptor loss or internalization might accompany increased levels of S1P ligand, we assessed S1P concentrations in the plasma and tumors of control and glioma-bearing mice by liquid chromatography-tandem mass spectrometry (LC-MS/MS). No differences were seen in the plasma, and intracranial CT2A gliomas instead showed slightly decreased levels of S1P compared to normal brain ( Supplementary Fig. 5e ,f).
We next looked for an association between T cell S1P1 levels and their sequestration in bone marrow across our various intracranial and subcutaneous tumor models. A strong inverse relationship was uncovered between T cell S1P1 levels and T cell numbers in bone marrow (Fig. 5c ). Furthermore, bone marrow T cell sequestration was associated with the presence of contracted spleens and thymuses ( Supplementary Fig. 5f,g ), suggesting such lymphoid organ contraction as contextually important.
We explored whether similar alterations in S1P1 were present in the bone marrow of subjects with GBM using flow cytometry. The results paralleled our findings in the murine models, with GBM subjects exhibiting decreased levels of S1P1 on the T cell surface compared to healthy, age-matched controls (Fig. 5d,e ). Likewise, an inverse relationship emerged between bone marrow T cell counts and surface S1P1 levels across GBM subjects and controls (Fig. 5f ).
Given these associations, we investigated whether forced loss of surface S1P1 on T cells might be sufficient to facilitate their sequestration. As shown in Fig. 4d-f , transferred T cells accumulated in the bone marrow of intracranial glioma-bearing mice after 24 h. This accumulation had not yet occurred at 2 h following transfer, which would have otherwise suggested active T cell homing to marrow. We theorized that the 24-hour delay was a function of the time needed for T cells to lose surface S1P1 when transferred into glioma-bearing recipients. Conversely, we hypothesized that T cells with prior loss of surface S1P1 would be subject to more immediate sequestration in mice bearing glioma.
To test this, we employed an S1P1 conditional knockout (S1P1-KO) mouse. Mice with loxP sites flanking exon 2 of S1pr1 were crossed with mice possessing inducible Cre recombinase 20 . When treated with tamoxifen, these mice demonstrate a decrease in S1P1 protein levels. Donor splenocytes were collected from tamoxifen-treated S1P1-KO mice and labeled with CSFE. These were injected via tail vein into intracranial CT2A-bearing recipients, and accumulation in bone marrow assessed at 2 h and 24 h postinjection. T cells from S1P1-KO mice accumulated in the bone marrow within 2 h, while cells from wild-type C57BL/6 (control) donors did not (Fig. 5g ). Similar results were obtained when S1P1 loss was instead imposed pharmacologically by treating recipient mice with the S1P1 functional antagonist FTY720 at the time of adoptive transfer ( Supplementary Fig. 5i ).
Hindering S1P1 internalization abrogates T cell sequestration in bone marrow. We next examined whether increased/stabilized surface S1P1 might abrogate bone marrow T cell sequestration in glioma-bearing mice. There currently exist no means for pharmacologically fixing S1P1 on the T cell surface. We thus employed an S1P1 'knock-in' (S1P1-KI) mouse strain in which lymphocyte S1P1 internalization is hindered (B6.129P2-S1pr1tm1.1Cys/J), resulting in stabilized cell surface receptor levels 21 . The S1P1 receptor in these mice has disrupted serine residues on the intracellular domain, precluding GRK2 phosphorylation, β -arrestin recruitment, and clathrin-mediated endocytosis.
We tested whether T cells possessing stabilized, internalizationdeficient S1P1 would resist sequestration when adoptively transferred into glioma-bearing mice. Recipient mice were C57BL/6 mice bearing intracranial CT2A. Donor T cells were collected from wildtype or S1P1-KI mice, CSFE-labeled, and injected intravenously. Bone marrow of recipient mice was analyzed at 2 h and 24 h posttransfer. At both time points, T cells from S1P1-KI donors failed to become appreciably sequestered within bone marrow when compared to T cells from wild-type donors (Fig. 6a) . Likewise, S1P1-KI mice themselves directly implanted with intracranial CT2A proved similarly resistant to bone marrow T cell sequestration (Fig. 6b) .
We therefore explored whether T cells 'liberated' from sequestration by S1P1 stabilization would travel to the intracranial compartment and effect an antitumor response. We examined intracranial CT2A tumors from both wild-type and S1P1-KI glioma-bearing mice. Tumor-infiltrating lymphocytes (TILs) were analyzed by flow cytometry and their number and phenotype characterized. Tumors from S1P1-KI mice contained higher numbers of CD3 + TILs than those from wild-type mice (Fig. 6c ). Likewise, CT2A-bearing S1P1-KI mice demonstrated increased proportions of CD3 + TILs possessing an activated, effector CD44 hi CD62L lo phenotype (Fig. 6d ). 
Fig. 5 | Loss of surface S1P1 on T cells directs their sequestration in bone marrow in the setting of intracranial tumors. a,
The percentage of nascent T cells expressing surface S1P1 was assessed by flow cytometry in the bone marrow of n = 6 control C57BL/6 mice or n = 6 mice bearing intracranial CT2A on day 18 following tumor implantation. b, Representative flow cytometry plot of data depicted in a. c, Negative correlation between bone marrow T cell counts and S1P1 levels on bone marrow T cells across intracranial and subcutaneous murine tumor models. Data in c were obtained from n = 6 intracranial CT2A, n = 5 intracranial E0771, n = 6 intracranial B16F10, n = 7 intracranial LLC, n = 6 subcutaneous CT2A, n = 7 subcutaneous E0771, n = 6 subcutaneous B16F10, and n = 7 subcutaneous LLC tumor-bearing mice. N = 21 control C57BL/6 mice were also included. Data in c are cumulative results from a minimum of two experiments with each tumor type. d, The percentage of nascent T cells expressing surface S1P1 was assessed by flow cytometry in the bone marrow of n = 14 GBM subjects or n = 12 age-matched controls. e, Representative flow cytometry plot of data depicted in d. f, Negative correlation between bone marrow T cell counts and surface S1P1 levels on bone marrow T cells in n = 12 GBM subjects and n = 10 age-matched controls. g, Relative sequestration of adoptively transferred CFSE-labeled T cells within the bone marrow of intracranial CT2A recipient mice either 2 h or 24 h after transfer (n = 5 mice per group). As indicated, transferred cells were splenocytes either from control C57BL/6 donors (control) or from S1P1 conditional knockout (S1P1-KO) donors. Data in g are representative findings from one of a minimum of two independently repeated experiments with similar results. All data in a, d, and g are shown as mean ± s.e.m. P values in a, d, and g were determined by two-tailed, unpaired Student's t-test. Two-tailed P values and Pearson coefficients for c and f are depicted.
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Despite displaying higher numbers of activated TILs, tumorbearing S1P1-KI mice that underwent no further intervention failed to consistently show improved survival. We hypothesized, however, that coupling S1P1 stabilization to T cell-activating therapies, such as 4-1BB agonism and/or checkpoint blockade, would have a synergistic effect, licensing the antitumor capacities of the newly freed T cells. Indeed, S1P1-stabilized (knockin) mice treated with a 4-1BB agonist demonstrated improved survival compared to the effects seen with either stabilized S1P1 or with 4-1BB agonism in wild-type mice alone (Fig. 6e ). Furthermore, in S1P1-KI mice themselves, whereas PD-1 blockade was ineffectual as monotherapy, the effects of 4-1BB agonism and checkpoint blockade proved additive, with the combination prolonging median survival and producing a 50% long-term survival rate ( Supplementary Fig. 6b ).
Again, as no pharmacologic means exist for stabilizing S1P1 on the T cell surface, we explored alternative translatable means for freeing sequestered T cells. We uncovered that treating CT2A glioma-bearing mice with granulocyte colony-stimulating factor (G-CSF) decreased bone marrow T cell counts and reversed T cell lymphopenia ( Supplementary Fig. 6a,b) . As with S1P1 stabilization alone, G-CSF monotherapy failed to consistently impact survival. When combined with 4-1BB agonism, however, a similar additive effect was achieved, yielding approximately 40% long-term survival.
( Supplementary Fig 6c) .
Discussion
The data reported here introduce sequestration as a novel mode of T cell dysfunction in cancer, specifically intracranial tumors. The S1P-S1P1 axis is proposed as the contributing mediator, with S1P1 loss on naïve T cells fostering their sequestration in bone marrow. Disturbances to T cell S1P1 are not previously reported in cancer, and T cell sequestration remains a mostly unaddressed mode of T cell dysfunction. While studies have revealed that cancer vaccines can elicit counterproductive T cell sequestration at sites of vaccine delivery 22 , there is little known about T cell sequestration that is tumor imposed. Sequestration of T cells may instigate their resultant antigenic ignorance, limiting their antitumor capacities 23 . Our data suggest the need for a new treatment scope within immunotherapy: strategies to reverse T cell ignorance. Given the results reported here, these strategies are anticipated to include S1P1 stabilization or overexpression, modalities not previously tested in cancer.
The role of the S1P-S1P1 axis in immunology continues to emerge. S1P1 and S1P4 are highly expressed by T cells, with S1P1 regulating T cell chemotactic responses 11, 24 , but also impacting resident memory commitment 25 , Treg induction 26 , and IL-6-dependent pathways 27, 28 . S1P1's chemotactic function has made it a newer treatment target for the multiple sclerosis drug fingolimod 27, [29] [30] [31] , whose aim is forced internalization of the S1P1 receptor on T cells to effect their sequestration in SLOs and decrease their transit to brain. Ironically, our data suggest that tumors of the intracranial As indicated, transferred cells were splenocytes either from control C57BL/6 donors (control) or from S1P1 stabilized knock-in (S1P1 KI) donors (n = 5 recipient mice per group). Data in a are representative findings from one of a minimum of two independently repeated experiments with similar results. b, T cell counts in the bone marrow of n = 10 intracranial CT2A-bearing wild-type C57BL/6 or n = 11 S1P1 KI mice. Counts were assessed at 18 d following tumor implantation and are shown relative to baseline counts in n = 6 tumor-naïve control wild-type or n = 6 tumor-naïve S1P1 KI mice. Cumulative data from three experiments are depicted in b. c, Intracranial CT2A tumors were harvested from n = 6 wild-type C57BL/6 (WT) or n = 6 S1P1 KI mice at 18 d following tumor implantation. TILs were assessed by flow cytometry and the number of total T cells per gram of tumor quantified. d, The frequency of activated effector (CD44 hi CD62L lo ) T cells in intracranial CT2A tumors from the same n = 6 wild-type C57BL/6 (WT) or n = 6 S1P1 KI mice in c was also quantified. Data in c and d are representative findings from one of a minimum of three independently repeated experiments with similar results. e, C57BL/6 (WT) or S1P1 KI mice were implanted with intracranial CT2A tumors and treated with a 4-1BB agonist antibody or isotype control (n = 8 per group). All data in a-d are shown as mean ± s.e.m. P values in a-d were determined by two-tailed, unpaired Student's t-test. Survival in e was assessed by two-tailed, generalized Wilcoxon test. P value for overall comparison is depicted.
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NATure MeDICINe compartment may usurp a previously unrecognized central nervous system capacity for eliciting this same phenomenon. Such a capacity may play a physiologic role limiting T cell access to the central nervous system and contribute to immune privilege. Subsets of patients with relapsing remitting multiple sclerosis experience a paradoxical exacerbation of multiple sclerosis and increase in brain-infiltrating Th17 CD4 + T cells when treated with fingolimod. Such patients frequently harbor a phosphorylationdefective S1P1, similar to our S1P1-KI mice, which likewise demonstrate an increase in TIL numbers 27 . We do not observe these to be Th17 polarized, however, which in the relapsing remitting multiple sclerosis patients may instead be a function of strong fingolimod agonism and resultant S1P1 signaling through the JAK-STAT3-IL17 pathway 27, 28 . This agonism is not present in our therapy model (we did not administer fingolimod to S1P1-KI mice), suggesting that interventions targeting S1P1 internalization more specifically (and not signaling) may be effective at guiding increased numbers of functional T cells into intracranial tumors. As S1P1 internalization is arbitrated by recruitment of β -arrestin to the receptor's intracytoplasmic components following GRK2mediated phosphorylation 32 , GRK2 and β -arrestin may represent new and promising therapeutic targets.
A possible detriment to S1P1 stabilization would be reductions to numbers of tissue resident memory T cells (T RM ), whose ability to establish themselves in non-lymphoid tissues depends on transcriptional downregulation of S1P1 25 . While such loss of T RM might prove restrictive for immunity at barrier tissue sites (skin, gastrointestinal or respiratory tract), the role of T RM in mediating immune responses in the brain is less clear 33 . Although T RM may accumulate in the brain during an acute viral infection 34 , no data are available regarding their prevalence or role in brain tumors. Our survival data suggest that loss of any present T RM within the tumor does not obviate a benefit to retaining S1P1 on the T cell surface. Likewise, the efficacy of fingolimod for multiple sclerosis suggests further that S1P1 + T cells are quite capable of trafficking to brain and eliciting local immune responses.
The mechanism of observed systemic T cell S1P1 loss remains an arena for future study. Both the lack of observed differences in S1P1 transcript levels in T cells from tumor-bearing mice, and the improved S1P1 levels seen with hindered receptor internalization, suggest that the defect is at the protein level, with the disturbance being either increased receptor internalization or delayed/failed receptor recycling. One study has reported increased levels of S1P ligand in GBM (a possible mechanism) 35 , although this study used normal gray matter rather than white matter as a control and we saw no such increase in ligand levels in either tumors or plasma by both ELISA and LC-MS/MS. Likewise, blockade of known transcriptional down-regulators of S1P1 that are prevalent in GBM, such as TGF-β , produced no effect on sequestration in our hands (data not shown). S1P1 loss and sequestration characterized predominantly naïve T cells in our studies. As such, it is perhaps not surprising that stabilizing S1P1 alone to free naïve T cells from the marrow had limited impact on survival as a mono-intervention. S1P1 stabilization, however, did license 41BB agonism and PD-1 blockade, the latter of which has already failed in clinical trials for recurrent GBM as a monotherapy 36 . The synergy we observed suggests that reduced T cell numbers are indeed a limiting factor for immunotherapeutic efficacy against intracranial tumors, and that reversal of T cell sequestration may serve as a useful therapeutic adjunct. The persistent benefits seen when genetic S1P1 stabilization was replaced with G-CSF imply that there may be available pharmacologic strategies for averting T cell sequestration.
Our findings also suggest that T cell sequestration may be a contributing factor to T cell lymphopenia in subjects with GBM. Numerous studies have highlighted T cell lymphopenia in this population 8, [37] [38] [39] , but many attribute the observation to the effects of treatment 40 . Our finding of pretreatment T cell lymphopenia contrasts with the work of others 40, 41 , but aligns with historical studies 42 . While radiation, temozolomide, and dexamethasone are certainly exacerbating, we reveal that T cell disappearances occur earlier and more severely than previously thought, extending to thymus and SLOs.
Lastly, our data indicate that a variety of tumors placed intracranially elicit bone marrow T cell sequestration, while none of the same tumors placed peripherally exhibit the same proclivity (Fig. 4a) . Others have reported differing capacities for the intracranial compartment to influence systemic immune function 43 . Given our findings, though, we anticipate that studies to understand and reverse sequestration will impact immunotherapeutic design not only for GBM patients, but for patients with intracranial metastases as well, a far larger population 44 . Other future goals will be to understand the observed lymphoid organ contraction, elucidate tumor-imposed S1P1 loss, and develop pharmacologic means for preventing S1P1 internalization.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41591-018-0135-2.
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Methods Clinical studies and specimen processing. All studies were conducted with approval from the Massachusetts General Hospital Cancer Center Institutional Review Board. We certify that all applicable institutional regulations concerning the ethical use of information from human subjects were followed during this research. For retrospective studies, records for all subjects with a diagnosis of GBM over a ten-year period at Massachusetts General Hospital were reviewed. Criteria for inclusion and exclusion are as outlined in the results section and patient characteristics are found in Supplementary Table 1 . For prospective studies, 15 treatment-naïve GBM subjects and 15 healthy, age-matched controls undergoing spinal fusion were included in the prospective collection of whole blood and bone marrow aspirates. Informed consent was obtained from all subjects. Bone marrow aspirates were collected under general anesthesia from the iliac crest. Using a 14-gauge needle, a total volume of 5 ml was collected. Both blood and bone marrow specimens were collected into purple top, EDTA-containing tubes. All blood and bone marrow samples were stored at room temperature and processed within 12 h. All samples were labeled directly with antibodies for use in flow cytometry, and red blood cells (RBCs) subsequently lysed using eBioscience RBC lysis buffer. Cells were washed, fixed, and analyzed on an LSRII FORTESSA flow cytometer (BD Biosciences). , and GR-1 (Catalog no. 553128, Clone: RB6-8C5, Lot no. 09439, 1:100) were obtained from BD Biosciences. Antibodies to murine S1P1 (Catalog no. FAB7089A, Clone: 713412, Lot no. ACNG0216051, 1:10) were obtained from R&D Systems. Probes for RNA PrimeFlow for mouse CD69, KLF2, and STAT3 were obtained from Life Technologies. For qPCR with reverse transcription, total RNA was isolated by RNeasy Mini Kit (Catalog no. 74104) from Qiagen. The assays were performed with Mouse S1P1 TaqMan (Catalog no. Mm02619656_s1) and Mouse GAPDH TaqMan (Catalog no. Mm03302249_g1) from ThermoFisher. In vivo therapeutic antibodies (anti-mouse PD-1 (Catalog no. BE0146, clone: RMP 1-14, Lot no. 640517M2) and 4-1BB agonist antibody (Catalog no. BE0169, clone: LOB12.3, Lot no. 647417M1)) were obtained from Bio-X-cell.
Reagents
Mice. Female C57BL/6, VM/Dk, and B6.129P2-S1pr1tm1.2Cys/J S1P1-KI mice were used at 6-12 weeks of age. The generation of B6.129P2-S1pr1tm1.2Cys/J (S1P1-KI) mice has been described 21 . S1P1-KI mice carry a Thr-Ser-Ser (TSS) to Ala-Ala-Ala (AAA) mutation in the C terminus (the last 12 amino acids) of the S1P1. This mutation leads to a loss in sensitivity for ligand-mediated receptor down-modulation, leading to partial block in the desensitization process and resulting in resistance to S1P-mediated S1P1 internalization in naïve T cells. Parental transgenic mice were acquired from the Jackson Laboratory with inhouse breeding colony expansion. C57BL/6 mice purchased from Charles River Laboratories were used as wild-type controls. S1P1 conditional knockout mice were created by crossing B6.129S6(FVB)-S1pr1tm2.1Rlp/J, which contains loxP sites flanking exon 2 of S1pr1 gene (JAX Stock no. 019141), with B6.Cg-Tg(UBCcre/ERT2)1Ejb/1J (JAX Stock no. 007001), which contains tamoxifen-inducible Cre. These two mice were obtained from the Jackson Laboratory and crossed and then back-crossed to obtain mice with the genotype flox/flox Cre (+ /− ). The mice were then treated with tamoxifen to induce recombination. VM/Dk mice were bred and maintained as a colony at Duke University. Animals were maintained under specific pathogen-free conditions at the Cancer Center Isolation Facility of Duke University Medical Center. All experimental procedures were approved by the Institutional Animal Care and Use Committee.
Cell lines. Murine SMA-560 malignant glioma, CT-2A malignant glioma, B16F10 melanoma, and LLC were kindly provided by Darell D. Bigner (Duke University, NC, USA), Robert L. Martuza (Massachusetts General Hospital, MA, USA), John H. Sampson (Duke University, NC, USA), and Glenn Dranoff (Dana-Farber Cancer Institute, MA, USA), respectively. Murine E0771 breast medullary adenocarcinoma was obtained from the American Tissue Culture Collection. SMA-560 cells are syngeneic on the VM/Dk mouse background, while all others are syngeneic in C57BL/6 mice. SMA-560, CT-2A, B16F10, and LLC cells were grown in vitro in DMEM with 2 mM 1-glutamine and 4.5 mg ml −1 glucose (Gibco) containing 10% FBS (Gemini Bio-Products). E0771 cells were grown in vitro in RPMI 1640 (Gibco) containing 10% FBS plus 1% HEPES (Gibco). Cells were collected in the logarithmic growth phase. For intracranial implantation, tumor cells in PBS were then mixed 1:1 with 3% methylcellulose and loaded into a 250-µ l syringe (Hamilton). The needle was positioned 2 mm to the right of the bregma and 4 mm below the surface of the skull at the coronal suture using a stereotactic frame. Then, 1 × 10 4 SMA-560, CT-2A, E0771, and LLC cells or 1 × 10 3 B16F10 cells were delivered in a total volume of 5 µ l per mouse. For subcutaneous implantation, 5 × 10 5 SMA-560, CT-2A, E0771, and LLC cells or 2.5 × 10 5 B16F10 cells were delivered in a total volume of 200 µ l per mouse into the subcutaneous tissues of the left flank. All cell lines have been authenticated using National Institute of Standards and Technology-published nine species-specific short tandem repeat markers to establish genetic profiles. Interspecies contamination check for human, mouse, rat, African green monkey, and Chinese hamster was also performed for each cell line. All cell lines have been tested negative for Mycoplasma spp. and karyotyped, and none are among the ICLAC database of commonly misidentified cell lines. The CellCheck Mouse Plus cell line authentication and Mycoplasma spp. testing services were provided by IDEXX Laboratories.
Murine tissue harvest. Spleen, thymus, CLNs, and long bones of the legs (femur and tibia) were collected at defined and/or humane end points, in accordance with protocol. For intracranial tumor-bearing animals, humane end points include inability to ambulate two steps forward with prompting. For subcutaneous tumorbearing animals, humane end points include tumor size greater than 20 mm in one dimension, 2,000 mm 3 in total volume, or tumor ulceration or necrosis. Spleens and thymuses were weighed before processing. Briefly, tissues were processed in RPMI, minced into single-cell suspensions, cell-strained, counted, stained with antibodies, and analyzed via flow cytometry. Bone marrow cells were flushed out from one femur and one tibia. Blood samples were directly labeled with antibodies and RBCs subsequently lysed using eBioscience RBC lysis buffer or BD Pharm Lyse (BD Biosciences). Spleen and bone marrow were subjected to RBC lysis before antibody labeling, while lymph nodes and thymus were labeled once single-cell suspensions were created. S1P1 flow cytometry. For S1P1 staining, all cell suspensions were prepared in staining buffer with the fixative agent (0.1% buffered neutral formalin (Sigma-Aldrich), 0.5% BSA (Sigma-Aldrich), and 2 mM EDTA (Gibco) in PBS). Cells were passed through 40-µ m nylon mesh cell strainers. After removing RBCs by BD Pharm Lyse lysing solution (BD Biosciences), cells were resuspended at a density of 5 × 10 6 to 2 × 10 7 cells per ml in the same staining buffer as described above and were aliquoted in a volume of 100 µ l. Cells were then incubated with either rat anti-mouse S1P1 APC-conjugated antibody (R&D systems) or mouse anti-human S1P1 eFlour 660-conjugated antibody (eBioscience) for 1 h at 4 °C and were washed once. Next, samples were incubated for 30 min at 4 °C with relevant antibody cocktails consisting of antibodies to additional markers (see Reagents section). Cells were analyzed with an LSRFortessa (BD Biosciences) and data were analyzed with FlowJo software.
Adoptive cell transfer. For tracking cells in vivo, the spleens from naïve C57BL/6 mice were processed into single-cell suspensions in RPMI 1640 (Gibco) containing 10% FBS (Gemini Bio-Products). Bone marrow single-cell suspensions from intracranial CT-2A tumor-bearing C57BL/6 mice were acquired from two femurs, two tibias, two humeri, and sternum to achieve maximum yield. Bone marrow cells were then enriched for T cells via the AutoMACS Pro Separator using the Pan T Cell Isolation Kit II, mouse with DEPLETE program (Miltenyi Biotec). Cells from spleens and bone marrow were labeled with CellTrace CFSE (Life Technologies). The labeled cells were transferred intravenously via tail veins (1 × 10 7 cells in 200 µ l PBS per mouse) into tumor-free or intracranial CT-2A tumor bearing C57BL/6 mice on day 18 after tumor implantation. The numbers of CFSE-positive T cells in the bone marrow were assessed by flow cytometry at specified time points following transfer.
ELISA. Relevant mice underwent retro-orbital bleed at predetermined time points using heparin-coated capillary tubes (VWR). Heparinized blood was then centrifuged and aliquots of plasma were stored at − 80 °C. S1P levels in murine plasma were analyzed using an S1P competitive ELISA kit (Echelon Biosciences) according to the manufacturer's instructions. 
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